untitled
|
|
- きみかず たけはな
- 7 years ago
- Views:
Transcription
1 IF mg 250mg 100mg 10mg 10mg Sodium Salicylate Sulpyrine Hydrate Caffeine Hydrate Allobarbital Procaine Hydrochloride FAX TEL FAX IF
2 IF 1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR Drug Safety Update IF
3 CAS
4 olbe tricker,clamann. ee unge isher asel 1915 astaldi 1914 iba ial 5 inhorn raun ichst ovocain 2 1
5 1 10mL 2 Sodium Salicylate Sulpyrine Hydrate Caffeine Hydrate Allobarbital Procaine Hydrochloride 3 2
6 4 C H NaO C13H16N NaO4S H2O C8 H10N4O2 H O C10H10N2O C13H10N2O2 HCl Monosodium 2-hydroxybenzoate Monosodium[(1,5-Dimethyl-3-oxo-2-phenyl-2,3- dihydro-1h-pyrazol-4-yl)-(methyl)amino] methanesulfonate monohydrate Trimethyl-1H-purine-2 6-3H 7H -dione monohydrate 5 5-Di-2-propenyl H 3H 5H -pyrimidinetrione 2- Diethylamino ethyl 4-aminobenzoate monohydrochloride 7 CAS CAS
7
8 mL H g 100mL H H g 20mL H
9 mL 2 ph ph ph mg 250mg 100mg 10mg 10mg 2 10mg (1000 ) () C 6
10 4 H mL 1 10 L H mol/L HC 9.6 L H mL 1 10 L H mol/L NaOH 10.0 L H
11 1 2 10mL 2.5mL
12 mL rithing SS 112.5mg kg Sp 87.5mg kg Cf 35.0mg kg Ab 3.5mg kg Pc 3.5mg kg 9
13
14 5 1 4) 5) ) 1,7 7) (2, CYP
15 ) 9) 6) 7)
16
17 6 1 [ AST(GOT) ALT(GPT) LDH CK(CPK) ]
18
19 AST(GOT) ALT(GPT) Al P 12 16
20
21 )
22 16 19
23 mL mL mL mL (i.p) (i.v) 10mL mg/kg ( ml/kg 813 mg/kg( ml/kg) 50 mg/kg ,600 2, mL
24 mg/kg mg/kg 288 mg/kg Ouchterloney 21
25 () mL AMX A
26 1 2 1 L.S Goodman and A.Gilman(Ed.) The Pharmacological Basis of Therapeutics,5th Ed.,331(1975) 2,,1779(1976) 3 ( ) (1977) 4 J.T.Wilson, et al. Clin.Pharmacol.Ther.,, (1978) 5 M.Volz,et al. Br.J.Clin.Pharmacol.,,299S-308S(1980) 6 H.Herbert,et al. J.Biol.Chem.,,315 (1957) 7 D.J.Harry,et al. Drug.Metab.Dispos.,, (1977) 8 T.Tsuchiya,et al. J.Pharm.Sci.,, (1971) 9 O.Christ,et al. Arzneim-Forsch.,, (1973) 10 Penttila,O.,et al. Brit.Med.J.,,470(1974) 11 Neuvonen,P.J. and Penttila,O. Brit.Med.J.,,535(1974) 12,(1),122(1995) 13,95(1983) ( ) (1977) 15 ( ) (1977) 16 ( ) (1977) 17, (8) 1868 (1973) 18(5),1070(1980) 23
27 24
1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR Drug Safety Update IF
2003 7 3 872189 873919 IF 1998 9 PROBEAN CAP. 1 250mg Polyenephosphatidylcholine 1998 9 16 1999 7 9 1999 7 FAX IF 2003 7 1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR
More informationIF 1 MR 63 2 IF 10 3 IF 2IF IF IF 3IF A4 9 IF IF IF 11 1 IF IF 4IF IF MR IF IF MR Drug Safety Update IF
2008 2 3 87269 IF19989 100g 700g 30g SucrosePovidoneIodine 1999 3 15 1999 7 9 2000 5 IF 2008 2 IF 1 MR 63 2 IF 10 3 IF 2IF IF IF 3IF A4 9 IF IF IF 11 1 IF IF 4IF IF MR IF IF MR Drug Safety Update IF 1981
More informationIF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug Safety Update() IF
200823 877122 IF19989 HYDROPHILIC OINTMENT 1g 250mg 200mg 120mg 60 40mg 10mg 1mg 1mg HydrophilicOintment 200821 19518 19977 IF20082 IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug
More information23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213
More information1999年3月作成(新様式第1版)
200622 19989 871313 1mL4mg JAN oxybuprocaine hydrochloridejan 2002621 20037 4 19667 1 FAX 2005 10 29607 05 1 63 () 103 2 3 49 111 4 Drug Safety Update 1. -------------------------------------1 2. -----------------------1
More information200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
More informationグリセオール注インタビューフォーム
2006 8 3 873999 871319 IF 1998 9 FAX 1 200mL 300mL 500mL 20g 30g 50g 10g 15g 25g 1.8g 2.7g 4.5g 0.9W/V 200mL500mL 1979 3 13 2004 7 9 1979 5 15 2006 8 300mL 1979 3 13 2004 7 9 1982 11 1 IF 1 MR 63 IF 10
More informationuntitled
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -
More informationエクラー軟膏0.3%、エクラークリーム0.3%、エクラーローション0.3%_IF
2005 1 872646 IF 1998 9 1g 3mg(0.3%) Deprodone Propionate 2003227 200374 1997415( ) 1998316( ) F A X 2003 7 1992 3 17 1997 10 9 1992 5 22 1997 12 19 IF 2005 4 IF 1. MR 63 2 IF 10 3 IF 2. IF IF IF 3. IF
More information-1-19 753-0214 TEL 083-927-7031083-927-7029 FAX 083-927-0214 e-mail a17201@pref.yamaguchi.lg.jp - 2 - -3-. 20kg 60% 2kg 2 3 -4-30 3 15 3-0.05 0.4 NaOH 0.5 20 -5-. 1 1,757g 69% 30 -6- -7- -8- C C H17 18
More information土壌中の重金属等簡易・迅速分析法
1 1 Geo-REX Geo-REX PC 9.8 kg 35 cm 20 cm 22 4.5cm2.7cm0.7cm AC100V50Hz/60Hz2A 5 35 30%RH80%RH 2 2. Geo-REX Geo-REX Geo-REX PC Geo-REX Geo-REX Geo-REX / ml 3 3. Geo-REX Geo-REX 4 0. 6.5 ph6 0.45 1 Geo-REX
More information土壌の観察・実験テキスト −土壌を調べよう!−
( ) 2006 7 20 i 21 1962 1969 1987 1992 2005 65 1972 1977 1997 1977 1998 1982 1998 2002 2004 2005 SPP 1999 ii 1 g cm m 6378km ( ) 4.2, 4.3 5.1 7.1 8.1 4.1 7.3, 7.4 7.1 1 2 7.1 8.2 2 5 6 1, 2 2.3 4.2, 4.3
More information:,, : - 7 -
31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6
More information0.5mg (mg 2mg 3mg 50mg 00mg 4mg mg 0.5mg/g 0.5mg/g mg/g 2mg/g mg mg 00mg 5mg 0mg 0mg 0mg 65mg/g 5mg L- 200mg 4mEq/g 2.5mEq 5mEq 50mg 00mg 05mg 25mg 00
042007 6 4 2 2 7 4 283 2 0 7 337 3 4 9 84 3 0 5 355 4 4 5 82 4 7 5 249 5 3 3 5 4 22 75 2 0 6 3 7 3 7 9 4 5 4 76 4 0 6 5 5 2 5 7 22 2 3 0 9 9 790 6 7 2 0.5mg (mg 2mg 3mg 50mg 00mg 4mg mg 0.5mg/g 0.5mg/g
More informationL- 19 L L- L-
0131001 15 1 31 49 35 145 14 5 19 4 23 15 3 10 7 15 634 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 L- 19 L- 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49
More information23 3 11 24 21 24 25 4 28 4 2 7 161 2,692 28 12 14 18 18 380 5 3 1 27 21 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213 640 416 82,979
More information後期化学_01_濃度
2011 ( ) 1 4 1 100 g g % * 1 100 g 1 g 1 % * 2 (1 g)/(100 g) = 0.01 = 1 % 100 g 100 g 99 g 100 g 1 g 1 % 2.5 g 50 g (2.5 g)/(50 g) = 0.050 = 5.0 % 100 ml g 1 %(w/w) wt% % %(w/v) % / 2 % SI 2 / % 100 ml
More informationNo.193 ( HPhttp://www.mhLw.go.jp/houdou/2003/09/h htmL)
Drug Information News No.193 ( HPhttp://www.mhLw.go.jp/houdou/2003/09/h0925-1.htmL) 2 No.192 HP DI [ ] 1. -1a - 50 100 300 2. 7501500 3000750 1500 3000 60009000 12000240006000 9000 12000 24000
More information医薬品リスク管理計画書
2.5 mg 3.75 mg 5 mg 20mg RMP 2.5 mg 3.75 mg 5 mg 20mg 87339 28 6 1.1 4 8 10 5 8 10 5 TTP 9 梗 6 TIA 11 6 1.2 11 CABG 12 12 13 13 15 2.5mg 15 2. 16 3. 16 4. 19 19 19 18 RMP 28 6 3 5 1 27 8 25 26 3 24 87339
More informationMicrosoft Word - 表紙資料2-4
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
More information1 z q w e r t y x c q w 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 R R 32 33 34 35 36 MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR
More informationuntitled
-- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5
More informationuntitled
NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.
More informationTaro10-mizushima01.PDF
- 1 - ATAGO N- % % g % g % g % g % g % g Brix% g g ml ml mgm / l ml mg mol/l mol/l mol/l ph NaSO mol/ l ml / g mg mg ml mol/l ml ml L- L- FIBE-MINI FIBE-MINI % % FIBE-MINI % g % g % g % C mg mg mg
More information温泉の化学 1
H O 1,003 516 149 124 2,237 1974 90 110 1km 2,400 ( 100 Mg 200 (98 ) 43,665 mg 38,695 mg 19,000 mg 2000 2000 Na-Ca-Cl 806 1970 1989 10 1991 4 ph 1 981 10,000 1993... (^^; (SO_4^{2-}) " " 1973-1987 1970
More information後期化学_04_酸塩基pH
2011 ( ) ph H3O + H + H3O + HCl H3O + HCl + H2O H3O + + Cl HCl H + + Cl OH OH NaOH OH NaOH Na + + OH NH3 OH NH3 + H2O NH4 + + OH 1 H + OH H + H + * 1 NH3 HCl NH4Cl NH4Cl NH3 + Cl NH3 + HCl NH4 + + Cl.
More information% %
4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5
More information(1)2004年度 日本地理
1 2 3 4 1 2 3 4 5 6 7 8 9 10 11 12-5.0-5.1-1.4 4.2 8.6 12.4 16.9 19.5 16.6 10.8 3.3-2.0 6.6 16.6 16.6 18.6 21.3 23.8 26.6 28.5 28.2 27.2 24.9 21.7 18.4 22.7 5 1 2 3 4 5 6 7 8 9 10 11 12 2.2 3.5 7.7 11.1
More information1320M/161320M
" # $ %! θθ v m g y v θ O v α x! O x y x α x y y " v # v sinα $ & v cosα ' v cosα v sinα ( v cosα % v sinα " g # gsinθ $ g sinθ ' g ( gsinθ ) g sinθ % gcosθ & g cosθ * gcosθ! g cosθ xy y L v g x xy L α
More information第4次酸性雨全国調査報告書(平成16年度) -(Ⅱ)付表編-
1.12.24 P. 5.4.3.1 NO NOP. 5.4.3.2P. 5.4.3.3 P. 5.4.3.4 P. 2.18 2.19 P. 2.20 P. 2.21 P. P. 5.5.2.11 SOA P. 5.5.2.12 NO B A B 1.1 16 mm FRS Vol. 31 42006 1.2 ph 16 FRS ms/m FRS 1.3 16 Vol. 31 42006 μmol/l
More information16 41 17 22 12 10
1914 11 1897 99 16 41 17 22 12 10 11 10 18 11 2618 12 22 28 15 1912 13 191516 2,930 1914 5,100 43 1.25 11 14 25 34364511 7.54 191420 434849 72 191536 1739 17 1918 1915 60 1913 70 10 10 10 99.5 1898 19034.17.6
More information製品案内 価格表 2014/4/1
4 (17) 3 43 5/20370/ 231(504,150) 11 12 10 14-16 10 3 100 17 100kg 5-6 3 13 3 18 18 # # # # #$$ %&$ ' ()* +,-% ' #). +,-%'% / ' # # #$ %&&&'( %)* +'(#$ #$ %&&&'( ++,-). +'(#$ #$ /'( + /0)- +'(#$ %&&&'(
More information3.ごみの減量方法.PDF
- 7 - - 8 - - 9 - - 10 - - 11 - - 12 - ( 100 ( 100 - 13-123,550,846 111,195,762 92,663,135 ( 12 25 37 49.2 16 33 49 65.6 15 30 44 59.0 2.5kg) ( 5kg) ( 7.5kg) ( k ( 123,550,846 111,195,762 92,663,135 (
More information新たな基礎年金制度の構築に向けて
[ ] 1 1 4 60 1 ( 1 ) 1 1 1 4 1 1 1 1 1 4 1 2 1 1 1 ( ) 2 1 1 1 1 1 1 1996 1 3 4.3(2) 1997 1 65 1 1 2 1/3 ( )2/3 1 1/3 ( ) 1 1 2 3 2 4 6 2.1 1 2 1 ( ) 13 1 1 1 1 2 2 ( ) ( ) 1 ( ) 60 1 1 2.2 (1) (3) ( 9
More information取扱説明書
ED-601 ED-501 ED-401 2 3 4 23 14 5 6 18 10 7 1 2 6 3 4 8 9 16 16 16 12 1 2 18 10 2 1 5 12 11 1 2 1 2 12 1 2 13 16 14 3 2 4 1 1 2 16 3 4 18 15 1 2 16 2 3 1 1 2 3 18 17 18 22 19 D A C 20 A B 22 B C D 22
More informationIF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF MR Drug Safety Update IF
2009 2 1 872612 IF 1998 9 IODINE M DISINFECTANT SOLUTION 10 10w/v 100mL 10g( 1g) PovidoneIodine 2008 10 15 2008 12 19 2009 1 6 IF 2008 12 IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF
More information23 3 11 21 24 28 4 31,371 20,822 34,511 21,720 12,278 9,574 7,502 137,778 1 69 83.49% 70 15.55% 0.96 3.61% 40 1.19% 1055 29.65% 28 10 1 2 230,250 43,150 656 138,000 137,832 137,820 121,000 30,000 246,800
More informationuntitled
1.4 特 許 状 況 - 1 - - 2 - 1.5 起 原 又 は 発 見 の 経 緯 及 び 開 発 の 経 緯 FCT CT RH ... 1.5-1... 1.5-1... 1.5-1... 1.5-1... 1.5-2... 1.5-2... 1.5-2... 1.5-3...1.5-4... 1.5-5 i 10mg FCT 1 1 6 15 5mg CT 1 1 2 6 4mg CT
More informationml ml ml mg ml ml mm mm mm mm mm mm mm mm mm mm mm ml mmhg mmhg ml Acetylcholine ml mg mm mm mm mm mm mm ope ++ Uribe Davis S H S S : : : : : : : : : G
More informationEPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
More informationありがとうございました
- 1 - - 2 - - 3 - - 4 - - 5 - 1 2 AB C A B C - 6 - - 7 - - 8 - 10 1 3 1 10 400 8 9-9 - 2600 1 119 26.44 63 50 15 325.37 131.99 457.36-10 - 5 977 1688 1805 200 7 80-11 - - 12 - - 13 - - 14 - 2-1 - 15 -
More informationEPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
More information公務員人件費のシミュレーション分析
47 50 (a) (b) (c) (7) 11 10 2018 20 2028 16 17 18 19 20 21 22 20 90.1 9.9 20 87.2 12.8 2018 10 17 6.916.0 7.87.4 40.511.6 23 0.0% 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2.0% 4.0% 6.0% 8.0%
More informationQ1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 A B (A/B) 1 1,185 17,801 6.66% 2 943 26,598 3.55% 3 3,779 112,231 3.37% 4 8,174 246,350 3.32% 5 671 22,775 2.95% 6 2,606 89,705 2.91% 7 738 25,700 2.87% 8 1,134
More information橡hashik-f.PDF
1 1 1 11 12 13 2 2 21 22 3 3 3 4 4 8 22 10 23 10 11 11 24 12 12 13 25 14 15 16 18 19 20 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 144 142 140 140 29.7 70.0 0.7 22.1 16.4 13.6 9.3 5.0 2.9 0.0
More information198
197 198 199 200 201 202 A B C D E F G H I J K L 203 204 205 A B 206 A B C D E F 207 208 209 210 211 212 213 214 215 A B 216 217 218 219 220 221 222 223 224 225 226 227 228 229 A B C D 230 231 232 233 A
More information1
1 2 3 4 5 (2,433 ) 4,026 2710 243.3 2728 402.6 6 402.6 402.6 243.3 7 8 20.5 11.5 1.51 0.50.5 1.5 9 10 11 12 13 100 99 4 97 14 A AB A 12 14.615/100 1.096/1000 B B 1.096/1000 300 A1.5 B1.25 24 4,182,500
More information05[ ]戸田(責)村.indd
147 2 62 4 3.2.1.16 3.2.1.17 148 63 1 3.2.1.F 3.2.1.H 3.1.1.77 1.5.13 1 3.1.1.05 2 3 4 3.2.1.20 3.2.1.22 3.2.1.24 3.2.1.D 3.2.1.E 3.2.1.18 3.2.1.19 2 149 3.2.1.23 3.2.1.G 3.1.1.77 3.2.1.16 570 565 1 2
More informationネットショップ・オーナー2 ユーザーマニュアル
1 1-1 1-2 1-3 1-4 1 1-5 2 2-1 A C 2-2 A 2 C D E F G H I 2-3 2-4 2 C D E E A 3 3-1 A 3 A A 3 3 3 3-2 3-3 3-4 3 C 4 4-1 A A 4 B B C D C D E F G 4 H I J K L 4-2 4 C D E B D C A C B D 4 E F B E C 4-3 4
More information/9/ ) 1) 1 2 2) 4) ) ) 2x + y 42x + y + 1) 4) : 6 = x 5) : x 2) x ) x 2 8x + 10 = 0
1. 2018/9/ ) 1) 8 9) 2) 6 14) + 14 ) 1 4 8a 8b) 2 a + b) 4) 2 : 7 = x 8) : x ) x ) + 1 2 ) + 2 6) x + 1)x + ) 15 2. 2018/9/ ) 1) 1 2 2) 4) 2 + 6 5) ) 2x + y 42x + y + 1) 4) : 6 = x 5) : x 2) x 2 15 12
More information目 次
1 2 3 t 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 IP 169 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67
More information(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12
(1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132
More informationMicrosoft Word - 00”ŒŁ\”ƒf.doc
1-1 1 1-2 5S 3 1-3 5 2-1 1 2-2 3 2-3 5 2-4 7 3-1 1 3-2 3 3-3 5 3-4 7 4-1 1977 1 4-2 1987 7 4-3 17 4-4 26 1-1 1 1-2 5S 3 1-3 5 1-1 (1) (2) (3) 1. -1-1 1:15 1:10 2.. owf / 1.0 40 1.0 3.0 60 3.0 80 kg 0.25
More information2 129-B*-006P 129-B*-007P C*-004P 129-D*-001P ADH B*-006P B*-007P C*-004P D*-001P Na
2.7.4 2.7.4.1 2.7.4.1.1 11 ADH 1 ADH 1 4 7 129-A*-003 129-B*-001 129-E*-001P 129-G*-001 129-H*-002 129-H*-004 129-H*-005 132 242 4 129-B*-004 129-C*-005P 129-H*-003 129-H*-006 44 ADH ADH 129-C*-001P 16
More information2014-11.key
2014-11 1 2 3 4 5 7 8 9 10 11 12 PC 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 45 46 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68
More information「東京こどもネット・ケータイヘルプデスク(こたエール)」平成22年度相談実績の概要
734, 35% 62, 11% 84, 16% 530, 26% 235, 11% PC) 396, 73% 579, 28% ) (21 ) 2 3 4 5 6 7 8 9 10 11 12 13 200 150 100 22 182 200 150 100 22 50 54 PC 49 52 PC 50 41 14 17 1 1 4 16 3 6 14 180 250 200 150 235
More information6 30 2005 10 1 65 2,682 00 21.9 481 1 2,776 21.0 15 1,740 00 5.8 107 13.6 40 2025 24.2-0 - -1 - -2 - -3 - -4 - -5 - -6 - -7 - -8- -9 - - 10 - -11 - - 12 - - 13-10 11 59 4 59 3 10 17 - 14 - - 15 - - 16
More information橡DI月報178.PDF
2002.5.10. DI 22-2668 HCV HCV 1 1 375mg/ 13 60mg 20mg 1 20mg 1 750mg 1 400mg 3 1 2 7 IAB IAB IAB IAB IAB HIV ( ) HIV CYP3A4 HIV ( ) CYP3A4 WBC CK CK 1) 2) Torsades de Pointes K ) ALT AST -GTP CYP2C9 CYP2C19
More information152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1
152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1 JAS 1-2 1-2 112 13 1-11-13 100870mg 100830mg11000 1100020.002 2 50 100 2 100 500 2 100 109252165 4514782 7 2.0kg 2-19220.05kg0.2kg
More information福島県2012-初校.indd
2012 FUKUSHIMA http://www.kairyudo.co.jp/ 2 4 5 1 2 3 2 3 20092008 kg cm 1500m 1000m 20m 50 m cm m 12 25.08 6.15 24.66 6.17 22.03 4.23 22.08 4.45 13 30.32 6.40 30.10 6.99 24.37 4.17 23.97 4.48 14 35.10
More information......IF
873959 CEREZYME injection IF20084 MR MR Drug Safety Update IF I. 1 3 2 3 II. 1 4 2 4 3 4 4 4 5 5 6 5 7CAS 5 III. 1 6 2 6 3 6 4 7 5 7 IV. 1 8 2 8 3 8 4 8 5 9 6 9 7 () 9 8 9 9 9 10 9 11 10 12 10 13 10 14
More information橡DI月報200.PDF
2004.3.2 DI 22-2668 15 10 WHIWomen s Health Initiative 15 8 Million women study HRT :1.24 2 1 :1.45 14 :1.74 59 :2.17 10 :2.31 HRT 1 :1.81 HRT :1.31 HRT 65 :2.05 CKCPK http://www.pharmasys.gr.jp http://www.mhlw.go.jp
More information医薬発1304_局外規第三部改正_.PDF
1304 12 12 21 11 3 23 343 Aldioxa Powder C 4 H 7 AlN 4 O 5 0.1 g 900 ml 2 50 20 ml 0.45 m 10 ml V ml 1 ml C 4 H 7 AlN 4 O 5 22 g ph 10.0 1 10 V ' ml 105 2 0.028 g 25 ml 1 ml ph 10.0 1 10 50 ml 223 nm A
More information2 Zn Zn + MnO 2 () 2 O 2 2 H2 O + O 2 O 2 MnO 2 2 KClO 3 2 KCl + 3 O 2 O 3 or 3 O 2 2 O 3 N 2 () NH 4 NO 2 2 O + N 2 ( ) MnO HCl Mn O + CaCl(ClO
1 [1]. Zn + 2 H + Zn 2+,. K Ca Na Mg Al Zn Fe Ni Sn Pb H Cu Hg Ag Pt Au H (H + ),,. [2] ( ) ( ) CO 2, S, SO 2, NH 3 () + () () + () FeS Fe S ( ) + ( ) ( ) + ( ) 2 NH 4 Cl + Ca(OH) 2 Ca O + 2 NH 3,.,,.,,.,.
More information1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
More informationi ( 23 ) ) SPP Science Partnership Project ( (1) (2) 2010 SSH
i 1982 2012 ( 23 ) 30 1998 ) 2002 2006 2009 1999 2009 10 2004 SPP Science Partnership Project 2004 2005 2009 ( 29 2010 (1) (2) 2010 SSH ii ph 21 2006 10 B5 A5 2014 2 2014 2 iii 21 1962 1969 1987 1992 2005
More information青森県2012-初校.indd
http://www.kairyudo.co.jp/ 2012 AOMORI 2 3 9 16 1 2 3 2010 6 128.9 128.2 128.7 8 9 31.7 30.0 31.7 30.0 22.5 21.4 21.9 21.0 117.2 116.7 116.3 115.8 65.1 64.9 64.7 64.5 7 25.3 24.0 24.9 23.5 123.1 122.5
More information50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
More informationまえがき
JAAS0012006 1 -------------------------------------------------------------------------------------------------------- 1 2 --------------------------------------------------------------------------------------------------------
More information攪拌シール攪拌棒 P50-1 P50-1 P , , , P50-6 P50-6 P , ,000 P50-2 P50-3 P L 500
図面による特注製作分析用セル 光学ガラス 研磨ガラス製品熔着角形バット 100 SUS SUS 550 550 550mm 3 5mm CO2 R NC 49 攪拌シール攪拌棒 P50-1 P50-1 P50-1-1 25 8 9 29 9 11,000-2 13,500-3 18,000 55-1 57 59 P50-6 P50-6 P50-6-1 9 29 9 70,000-2 75,000 P50-2
More informationL 150M 200S ,880 9,000 12,
5 3-347-430 10,440 305317 1.4L 195200 606 1 3-330-105 6,000 3-347-494 17,800 3-334-325 7,920 3-334-326 7,920 218230 3-334-320 7,920 3-334-321 7,920 100 220230 3-347-465 6,900 220230 2 200255000 3-347-467
More information